Message

From: Kashtock, Michael E [Michael.Kashtock@fda.hhs.gov]
Sent: 10/26/2016 8:04:44 PM
To: Herndon, George [Herndon.George@epa.gov]
CC: South, Paul [Paul.South@fda.hhs.gov]; Sack, Chris A [Chris.Sack@fda.hhs.gov]; Liang, Charlotte [Charlotte.Liang@fda.hhs.gov]; Robin, Lauren P [Lauren.Robin@fda.hhs.gov]; Hrdy, David [Hrdy.David@epa.gov]
Subject: Inadvertent residues

Jeff,

I've gone back over some d Deliberative Process / Ex. 5 A few things arise.

Deliberative Process / Ex. 5

Deliberative Process / Ex. 5

Deliberative Process / Ex. 5

FYI, I'm including a link to a web publication from a DC law firm that discusses this exemption approach; see https://www.khlaw.com/562. The full text of the FQPA is at https://www.congress.gov/bill/104th-congress/house-bill/1627/text?overview=closed.

Michael E. Kashtock, Ph.D.
Division of Plant Products and Beverages
Office of Food Safety
Center for Food Safety and Applied Nutrition
Food and Drug Administration
240-402-2022
301-436-2632 FAX